KZA Insider Trading

Insider Ownership Percentage: 18.60%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Kazia Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Kazia Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kazia Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for KZA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Kazia Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/20/2023Steven CoffeyInsiderBuy135,000A$0.12A$16,200.00
3/13/2023Bryce CarmineInsiderBuy135,000A$0.12A$16,200.00
3/3/2023Bryce CarmineInsiderBuy181,819A$0.11A$20,000.09
9/7/2022James GarnerInsiderBuy100,000A$0.23A$23,100.00
12/20/2021Steven CoffeyInsiderBuy50,000A$1.08A$54,150.00
8/27/2021James GarnerInsiderBuy20,000A$1.38A$27,620.00
6/2/2021Steven CoffeyInsiderBuy8,000A$1.25A$9,968.00
5/31/2021James GarnerInsiderBuy10,000A$1.24A$12,430.00
5/3/2021James GarnerInsiderBuy20,000A$1.39A$27,880.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Kazia Therapeutics (ASX:KZA)

13.51% of Kazia Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
Read More on Kazia Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

47,736 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

5.93%

Beta

2.12

Who are the company insiders with the largest holdings of Kazia Therapeutics?

Kazia Therapeutics' top insider investors include:
  1. Bryce Carmine (Insider)
  2. James Garner (Insider)
  3. Steven Coffey (Insider)
Learn More about top insider investors at Kazia Therapeutics.